Clinical Trial

Study to Evaluate the Effects of AV-001 on HD-induced Brain Injury.

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
Cognitive decline is increasingly recognized among patients receiving maintenance hemodialysis (HD). This can include trouble remembering, slower thinking or mentally feeling foggy. This research is being done to determine if a new medication (AV-001) can protect the brain from injury caused by hemodialysis by strengthening blood vessels in the brain and reducing inflammation. If successful, this research could lead to better protection for the brains of people undergoing regular dialysis, potentially reducing the risk of cognitive decline and stroke.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-11-14.
Status change: Not Yet Recruiting → Recruiting 2026-04-15
Trial Details
NCT Number NCT07234890
Lead Sponsor London Health Sciences Centre Research Institute
Collaborators: Vasomune Therapeutics, Inc.
Conditions Hemodialysis
Enrollment 60 participants
Start Date 2025-12-16
Primary Completion 2027-12-31 (estimated)
Study Completion 2027-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-04-17